文献速递肝病消化道出血

根据肝硬化临床分期调整治疗以改善食管胃静脉曲张出血的一级预防:个体参与者数据的竞争风险Meta分析

Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data.
PubMed 文献 · Aliment Pharmacol Ther · 2023-12-18

该系统评价与竞争风险Meta分析纳入11项RCT的1400例高危静脉曲张无出血史患者,比较非选择性β受体阻滞剂(NSBBs)与内镜下静脉曲张套扎术(EVL)对生存的影响。在代偿期肝硬化患者中,EVL较NSBBs死亡风险更高(sHR=1.76,95%CI=1.11-2.77),NSBBs+EVL较NSBBs无显著降低;在失代偿期患者中,各治疗间死亡风险相似。作者认为代偿期患者预防治疗时NSBBs更可取。

要点

  • 代偿期肝硬化伴高危静脉曲张患者,EVL较NSBBs死亡风险更高(sHR=1.76,95%CI=1.11-2.77)。
  • 代偿期患者中NSBBs+EVL较NSBBs死亡风险无显著降低,异质性I²=0%。
  • 失代偿期患者中EVL与NSBBs、联合治疗与单药治疗的死亡风险相似。

核心结论

  • 在代偿期肝硬化伴高危静脉曲张的一级预防患者中,NSBBs较EVL显著改善生存,加用EVL无额外获益。
  • 在失代偿期患者中,两种治疗的生存相似。
  • 该研究提示,在代偿期患者中建议预防治疗时NSBBs更可取。

研究设计与样本

  • 通过系统综述识别比较NSBBs与EVL(单药或联合)用于一级出血预防的RCT。
  • 采用竞争风险、时间-事件Meta分析,使用从RCT主要研究者获得的个体患者数据(IPD)。
  • 25项RCT符合条件,14项未能提供IPD,11项纳入分析,共1400例患者(代偿期656例,失代偿期744例)。
  • 患者接受NSBBs(N=625)、EVL(N=546)或NSBB+EVL(N=229)治疗。
  • 分析按既往肝硬化失代偿分层,组间基线特征相似。

主要发现

  • 总体死亡风险EVL vs NSBBs相似(sHR=1.05,95%CI=0.75-1.49),EVL+NSBBs vs 任一单药治疗亦相似,异质性低(I²=28.7%)。
  • 代偿期患者中,EVL vs NSBBs死亡风险更高(sHR=1.76,95%CI=1.11-2.77)。
  • 代偿期患者中,NSBBs+EVL vs NSBBs死亡风险无显著降低,无异质性(I²=0%)。
  • 失代偿期患者中,EVL vs NSBBs及NSBBs+EVL vs 任一单药治疗的死亡风险相似。

临床怎么用

  • 作者认为,在代偿期肝硬化伴高危静脉曲张患者中,建议预防治疗时NSBBs更可取。

局限性

  • 25项符合条件RCT中14项未能提供个体患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-selective β-blockers (NSBBs) and endoscopic variceal-ligation (EVL) have similar efficacy preventing first variceal bleeding. Compensated and decompensated cirrhosis are markedly different stages, which may impact treatment outcomes. We aimed to assess the efficacy of NSBBs vs EVL on survival in patients with high-risk varices without previous bleeding, stratifying risk according to compensated/decompensated stage of cirrhosis. METHODS: By systematic review, we identified RCTs comparing NSBBs vs EVL, in monotherapy or combined, for primary bleeding prevention. We performed a competing-risk, time-to-event meta-analysis, using individual patient data (IPD) obtained from principal investigators of RCTs. Analyses were stratified according to previous decompensation of cirrhosis. RESULTS: Of 25 RCTs eligible, 14 failed to provide IPD and 11 were included, comprising 1400 patients (656 compensated, 744 decompensated), treated with NSBBs (N = 625), EVL (N = 546) or NSBB+EVL (N = 229). Baseline characteristics were similar between groups. Overall, mortality risk was similar with EVL vs. NSBBs (subdistribution hazard-ratio (sHR) = 1.05, 95% CI = 0.75-1.49) and with EVL + NSBBs vs either monotherapy, with low heterogeneity (I2 = 28.7%). In compensated patients, mortality risk was higher with EVL vs NSBBs (sHR = 1.76, 95% CI = 1.11-2.77) and not significantly lower with NSBBs+EVL vs NSBBs, without heterogeneity (I2 = 0%). In decompensated patients, mortality risk was similar with EVL vs. NSBBs and with NSBBs+EVL vs. either monotherapy. CONCLUSIONS: In patients with compensated cirrhosis and high-risk varices on primary prophylaxis, NSBBs significantly improved survival vs EVL, with no additional benefit noted adding EVL to NSBBs. In decompensated patients, survival was similar with both therapies. The study suggests that NSBBs are preferable when advising preventive therapy in compensated patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Villanueva C, Sapena V, Lo GH, et al. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Aliment Pharmacol Ther. 2023. PMID: 38108646. doi:10.1111/apt.17824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。